I actually really enjoyed the clinical correlate given by Dr. Keyser about hemostasis. A real patient came and described an episode of heparin induced thrombocytopenia. Basically, we were supposed to retain that heparin is infused into patients to reduce blood clotting. This ties into how the pharmacodynamic effect of these drugs work by inhibiting clotting factors along the coagulation cascade. For some reason, the drug had the reverse effect on this particular patient. Anyways, there is much to learn if I ever want to work in an anticoagulation clinic.
Last weekend, Monica Iskandar threw the AIDS Mosaic Variety show to finish off the AIDS action week series of lunchtime lectures. We even had our biochem professor perform in one of the hip hop numbers. Check it out below on youtube.
http://www.youtube.com/watch?v=Ix3CUd5EVZs
Today, we had one of the authors of our Pharmacy Law book (Bill Marcus) come and give a review for our CP115 final. A tip for any of you who need to buy this book next year, the book is available at a signifigant discount from the california pharmacist magazine; it is sold by CPhA. So check out the pharmacist organizations for better prices for new textbooks than the bookstore.
Dr. Marcus actually did a pretty good job reviewing the main points that we should take with us. The legal ratio of pharmacy interns to techs to licensed pharmacists working at the same time, the special exceptions for a CII as opposed to CIII-V drugs when filling a prescription, all the DEA forms necessary in the transfer, dispensing of controlled substances, and information that a pharmacist can correct but not enter on a prescription, legal importation of drugs, etc. So much material that I am dreading to have to memorize for the boards 3 years from now. And apparently, there will be new serial RX forms that can be issued for patients to fill CII drugs at a later date legally. Currently, it is illegal to refill a CII drug like ritalin or oxycodone.
Time to stop procrastinating and start studying.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment